NCT02273739 - Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2014

Primary Completion Date

June 3, 2016

Study Completion Date

June 3, 2016

Conditions

Solid TumorGliomaAngioimmunoblastic T-cell LymphomaIntrahepatic CholangiocarcinomaChondrosarcoma

Interventions

DRUG

Enasidenib

Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.

Trial Locations (12)

New York

Baltimore

Miami

Nashville

Cleveland

Omaha

Dallas

Los Angeles

Los Angeles

Villejuif

Boston

Bordeaux